<code id='843344F261'></code><style id='843344F261'></style>
    • <acronym id='843344F261'></acronym>
      <center id='843344F261'><center id='843344F261'><tfoot id='843344F261'></tfoot></center><abbr id='843344F261'><dir id='843344F261'><tfoot id='843344F261'></tfoot><noframes id='843344F261'>

    • <optgroup id='843344F261'><strike id='843344F261'><sup id='843344F261'></sup></strike><code id='843344F261'></code></optgroup>
        1. <b id='843344F261'><label id='843344F261'><select id='843344F261'><dt id='843344F261'><span id='843344F261'></span></dt></select></label></b><u id='843344F261'></u>
          <i id='843344F261'><strike id='843344F261'><tt id='843344F261'><pre id='843344F261'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:1334
          the U.S. Medicare Handbook is photographed in Washington.
          Pablo Martinez Monsivais/AP

          Roughly 33.4 million adults older than 65 and people with disabilities were enrolled in a Medicare Advantage plan as the calendar flipped to 2024 — another year of steady, albeit slower, growth for the taxpayer-funded program.

          Enrollment increased 7.1% year over year, which would make this year’s annual growth rate identical to last year’s, according to new federal Medicare Advantage enrollment data analyzed by STAT.

          advertisement

          The data reinforce how America’s Medicare program continues to shift toward a more privatized version that has not saved any money for taxpayers, has been linked to inappropriate coding practices, and has restricted care for older and vulnerable patients. And even though the federal government made several changes to Medicare Advantage for 2024 — changes that were vehemently opposed by the health insurance industry — the program’s growth has not been stunted, nor did insurers dramatically slash their offerings.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Roche acquires Telavant from Roivant, adding experimental IBD treatment
          Roche acquires Telavant from Roivant, adding experimental IBD treatment

          SebastienBozon/AFPviaGettyImagesRochesaidMondayitwasbuyingTelavantHoldingsfor$7.1billionupfront,pick

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          STAT Summit: How researchers deal with rejection

          Fromlefttoright:BrendaCabrera-Mendoza,LaurenGhazal,andZhiYuatthe2023STATSummit.STATAttheageof26,Laur